Biomea Fusion, Inc. announced the appointment of Juan Pablo Frías, M.D. as Chief Medical Officer (CMO). In his new role, Dr. Frías will leverage his deep industry and clinical investigator expertise in the development of therapeutics for the management of diabetes to oversee the clinical development of BMF-219, Biomea?s novel investigational menin inhibitor, for the treatment of type 2 and type 1 diabetes. Steve Morris, M.D., will transition to the new role of Chief Development Officer (CDO), where he will continue to lead clinical development of Biomea?s oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.

Dr. Frías is a board-certified endocrinologist who has served as principal investigator on over 250 clinical diabetes studies, with over half of those being Phase III studies, and has participated in the clinical development of more than 20 approved diabetic agents, including Mounjaro? (tirzepatide?s SURPASS trials), Ozempic® (semaglutide?s STEP, SUSTAIN, and SUSTAIN FORTE trials), Trulicity® (dulaglutide?s AWARD trials), and Farxiga (dapagliflozin?s DURATION studies). Dr. Frías is a board member of the nonprofit T1D Exchange and a member of the clinical advisory boards to five of the top pharmaceutical companies in the diabetes care market.

He has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson & Johnson, where he served as CMO and Global Vice President of Clinical and Medical Affairs, Diabetes Care. Dr. Frías has also held academic positions at the University of Colorado Health Sciences Center, Barbara Davis Center for Diabetes, and the University of California San Diego School of Medicine, where he currently serves on the clinical faculty. He has published over 125 articles in peer reviewed journals; his numerous publications in this field include first author publications in the New England Journal of Medicine, Lancet, Lancet Diabetes and Endocrinology, Diabetes, Diabetes Care, and Cell Metabolism.